Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director

Slides:

Advertisements

Similar presentations

DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.

Advertisements

Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.

New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.

Dr R Ramachandran 5 th Joint International Monitoring Mission to Review NTP Thailand 5th JMM Thailand.

TBD-UK: The UK response in the discovery and development of new TB drugs. Dr Geoff Coxon Deputy Leader & Director of Medicinal Chemistry, TBD-UK APPG-TB.

1 |1 | Implementing HIV and TB Diagnostics in Resource Cape Town, South Africa, September 23 rd, 2014 New diagnostic technologies in development and target.

Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.

Christine Lubinski Vice President for Global Health Infectious Diseases Society of America April 17, 2009 Germs Go Global Tuberculosis and HIV/TB Co-Infection.

Access to TB Drugs and Diagnostics Gregg Gonsalves Open Society Foundations Division of the Epidemiology of Microbial Diseases, Yale School of Public Health.

TB/HIV: Impact and Opportunities Helene Gayle, MD, MPH Bill and Melinda Gates Foundation DATE, 2004.

Accelerating PMDT scale up in Ethiopia

Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.

TUBERCOLOSIS Agis Terzidis, Paediatrician Spyridon Gialamas, Medical Doctor SEMINAR ON TROPICAL AND TRAVEL MEDICINE AT TTCIH IFAKARA 25 JUNE 2009.

Tuberculosis quick facts Illustrated through drawings from children across the Region Philippines.

The Work of WHO in the South-East Asia Region The Work of WHO in the South-East Asia Region Biennial Report of the Regional Director 1 January

Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.

1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.

22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.

Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.

Module 1: Overview of tuberculosis (TB) and TB diagnostics Global Laboratory Initiative – Xpert MTB/RIF Training Package.

Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,

TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.

RNTCP: DOTS Expansion and plans for DOTS-Plus

PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,

Bi-State TB Elimination April 10, 2014 Anna Frye Michelle Goodyear Tuberculosis: Recent Trends and Relevant Research.

DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.

Partnerships in TB Vaccine Research & Development

Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.

TASK FORCE ON RETOOLING STOP TB PARTNERSHIP Cape Town November 2007.

WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.

The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.

Epidemiology of tuberculosis. Peymane Adab, Richard Fielding, Susana Castan.

TB and Poverty in The Global Plan to Stop TB Valerie Diaz, Sarah England, Knut Lönnroth, Giorgio Roscigno Stop TB Partnership Stop TB Department,

Experience with Tb diagnostics and Scale up of services Botswana, Nigeria, and Tanzania Ernest Ekong, MD,MPH National Clinical Coordinator Harvard PEPFAR.

U pdates on the development of the NTP National Strategic Plan GC National TB Conference Pokhara, July 14-15, 2014 Giampaolo Mezzabotta Medical.

FIND Ongoing Activities What’s in the pipeline for Rapid DST? WHO Stop TB Department Supranational Reference Laboratory Network Meeting Paris, October.

1 FIND and Operational Research in HIV-Associated Tuberculosis Rick O’Brien Foundation for Innovative New Diagnostics, Geneva.

R&D for TB: Updates & Opportunities for the Private Sector Christian Lienhardt Senior Scientific Advisor, Stop TB Partnership WHO, Geneva GBC Conference.

1 |1 | Dr Karin Weyer Stop TB Department Geneva, Switzerland Strategic guidance on the use of laboratory technologies DEWG Meeting, Geneva: 13 October.

PREVALENCE OF MDR-TB AMONGST PATIENTS WITH HIV AND TB CO- INFECTION SEEN AT THE DOTS CLINIC OF N.I.M.R., LAGOS, NIGERIA. Enya V.N.V, Onubogu C.C., Wahab.

Update of the Global Plan to Stop TB TB/HIV Working Group Meeting Geneva, November 2009 Christian Lienhardt.

End TB Strategy HCW with cough since January. Seen at government clinic thrice with no sputum/CXR. Diagnosed TB in May only.

INAT and Research Christian Lienhardt Stop TB Partnership Geneva First Meeting of the Core Group of the Subgroup on Introducing New Tools and Approaches.

Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.

Harvard University Initiative for Global Health Global Health Challenges Social Analysis 76: Lecture 8.

Tuberculosis control in Suriname Situational analysis.

TB Control Measures: From development and endorsement to adoption and implementation Léopold Blanc TBS Stop TB department WHO Christy Garcia University.

Tuberculosis Trials Consortium (TBTC) Overview Completed, Ongoing, and Moxifloxacin Clinical Trials Kenneth G. Castro, M.D. Assistant Surgeon General,

The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.

Meeting of the Working Group on TB Drug Development Why you need to be engaged? Marcos Espinal Executive Secretary Stop TB Partnership 29 October 2004.

Contribution of operational research in China National Center for TB Control and Prevention, China CDC Jiang Shiwen Cancun.

Revolutionizing TB Control with Innovation in New Diagnostics Dr Giorgio Roscigno Chief Executive Officer, FIND Reversing the Tide: the End of Tuberculosis,

LEARNING MODULE TITLE SUBTITLE. HISTORY OF PRESENT ILLNESS An 18 year-old woman with no past medical history and no known risks for TB presents with several.

$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.

American Public Health Association – Annual Meeting 2007 Politics, Policy and Public Health Session : Institutionalizing Tuberculosis Control Strengthening.

Tuberculosis - the opportunity in our lifetime Dr. Lucica Ditiu | Executive Secretary | Stop TB Partnership 09.April.2013 | Brussels, Belgium.

Peter Cegielski, MD, MPH Team Leader for Prevention, Care and Treatment Global Tuberculosis Branch Division of Global HIV and TB Reinforcing the Surveillance.

PMDT IN CHINESE TAIPEI ECONOMY Anita Pei-Chun Chan, MD, PhD Medical Officer, TCDC Associated Director, TB Research Center, TCDC Assistant Professor, Institute.

World Tuberculosis Day 2016 Monitoring the implementation of the Framework Action Plan to Fight Tuberculosis in the European Union – Situation in 2014.

TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.

Charles D. Wells, MD Chief, International Research and Programs Branch

World Tuberculosis Day 2014

Summary of changes in the RNTCP technical guidelines in

Accessing Medicines in Africa Prospects and challenges

The Commission Strategy on TB vaccine research

Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries Kathrin Zürcher, Marie Ballif, Lukas Fenner, Sonia.

World Tuberculosis Day 2016

World Tuberculosis Day 2014

TB epidemiological situation in Kyrgyzstan

The STOP TB Strategy – 2009 VISION: A TB-free world

Presentation transcript:

Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director

KNCV Tuberculosis Foundation  Established in 1903 in the Netherlands  Mission – Global elimination of tuberculosis through the development and implementation of effective, efficient and sustainable tuberculosis control strategies  Core activities -Program support -Human resource development -Policy development -Epidemiological and operational research -Strengthening awareness -Fundraising

Active in more than 40 countries; approximately three million patients are traced annually worldwide: more than 85% of these recover Active in more than 40 countries

ACTUAL DATA TUBERCULOSIS  9.4 MILLION INCIDENT CASES  1.8 MILLION DEATHS (500,000 CO-INFECTED)  MDR-TB CASES  Case Detection Rate N+: 61%  Case Detection Rate MDR-TB: 7%  Treatment Success Rate N+: 87%  Treatment Success Rate MDR-TB: 60%

Do you know?

Recent Developments NEW DIAGNOSTICS  WHO endorsement of: a) new smear positive case definition b) reduced no. of sputum specimens examined by smear microscopy c) liquid culture, rapid speciation and DST d) line probe assays for rifampicine and INH resistance Several large-scale multi-country trials of new tools underway

Recent Developments NEW DRUGS  Clinical Development Phase 3: 1 product  Clinical Development Phase 2: 2 products  Discovery Phase 2 (optimization): 6 products  Discovery Phase 1 (identification): 11 products

Recent Developments NEW VACCINS Keeping the Pipeline filled More than 40 TB vaccine candidates in the preclinical TB vaccine pipeline Performing clinical trials 6 TB vaccine candidates have entered Phase I (safety) clinical trials 3TB vaccine candidates have entered Phase II (immunogenicity) trials 1 TB vaccine candidate has entered Phase III (efficacy) clinical trials

Requirements from the field  RESPONDING TO IDENTIFIED NEEDS  EFFECTIVE  AFFORDABLE  CONTRIBUTING TOWARDS EQUITY  HUMAN RESOURCES FRIENDLY

Mohandas Gandhi The difference between what we do and what we are capable of doing would suffice to solve most of the world’s problems